This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

KeyBanc Sticks to Their Buy Rating for Resmed (RMD)

Tipranks - Tipranks - Tue Jun 23, 1:38AM CDT

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed, with a price target of $266.00.

TipRanks' Prime Week Sale - 70% Off

According to TipRanks, Fishbin is an analyst with an average return of -8.7% and a 32.39% success rate. Fishbin covers the Healthcare sector, focusing on stocks such as Resmed, ICU Medical, and Solventum Corporation.

In addition to KeyBanc, Resmed also received a Buy from Citi’s Laura Sutcliffe in a report issued on June 15. However, on June 17, Morgan Stanley downgraded Resmed (NYSE: RMD) to a Hold.

See the top stocks recommended by analysts >>

Based on Resmed’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.43 billion and a net profit of $398.73 million. In comparison, last year the company earned a revenue of $1.29 billion and had a net profit of $365.04 million

Read More on RMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).